[The Current and Future Status of Perioperative Therapy in Pancreatic Cancer]

In metastatic pancreatic cancer, combined chemotherapy such as FOLFIRINOX and gemcitabine plus nab-paclitaxel became standard of care. Current standard of care in preoperative settingwas adjuvant S-1 for 6 months in Japan. Neoadjuvant gemcitabine plus S-1 became the new standard in 2019. In Western countries, gemcitabine plus capecitabine and modified FOLFIRINOX without bolus 5-FU and with reduction of irinotecan to 150mg/m2 became standard of care. We will implement in current and future status of preoperative therapy.